Endocrine, Cardiovascular, Pharmacological, and Physiological Aspects of Sex Hormone Therapy in Turner Syndrome - Study 1

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518557-42-00

Enrollment

Registered

2024-10-23

Start date

2021-11-29

Completion date

Unknown

Last updated

2024-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Turner syndrome

Brief summary

Equipotency: Levels of luthenizing hormone and follicle stimulating hormone are measured at different doses

Interventions

DRUGEstrofem

DRUGfilmovertrukne tabletter

DRUGDivigel 1 mg gel

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Equipotency: Levels of luthenizing hormone and follicle stimulating hormone are measured at different doses	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026